Cognition Therapeutics Inc (NASDAQ:CGTX)’s traded shares stood at 0.43 million during the last session, with the company’s beta value hitting 1.53. At the close of trading, the stock’s price was $1.90, to imply a decrease of -6.86% or -$0.14 in intraday trading. The CGTX share’s 52-week high remains $3.20, putting it -68.42% down since that peak but still an impressive 52.63% since price per share fell to its 52-week low of $0.90. The company has a valuation of $76.11M, with an average of 141.76K shares over the past 3 months.
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
After registering a -6.86% downside in the last session, Cognition Therapeutics Inc (CGTX) has traded red over the past five days. The stock hit a weekly high of 2.29, dropping -6.86% in its intraday price action. The 5-day price performance for the stock is -13.64%, and -16.30% over 30 days. With these gigs, the year-to-date price performance is 2.70%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cognition Therapeutics Inc (CGTX) estimates and forecasts
Looking at statistics comparing Cognition Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Cognition Therapeutics Inc (CGTX) shares are 2.70% up over the last 6 months, with its year-to-date growth rate lower than industry average at -12.79% against 15.70%.
CGTX Dividends
Cognition Therapeutics Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Cognition Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
